Rational design of adjuvants boosts cancer vaccines

Prog Mol Biol Transl Sci. 2024:209:101-125. doi: 10.1016/bs.pmbts.2024.03.001. Epub 2024 Mar 22.

Abstract

Cancer vaccines are expected to be next breakthrough in cancer immunotherapy. In cancer vaccines, adjuvants play an important role by enhancing and reshaping tumor antigen-specific immune responses. Failures in previous cancer vaccine clinical trials can be attributed to inappropriate selection and design of tumor antigens and adjuvants. Using basic theories of tumor immunology, the development of sequencing technology and nanotechnology enables the creation of cancer vaccines through appropriate selection of tumor antigens and adjuvants and their nanoscale assembly based on the specific characteristics of each tumor. In this chapter, we begin by discussing the various types of cancer vaccines and categories of tumor antigens. Then, we summarize the classification of adjuvants for cancer vaccines, including immunostimulatory molecules and delivery systems, and clarify the various factors that influence the properties of adjuvants, such as chemical composition, structure, and surface modification. Finally, we provide perspectives and insights on rational design of adjuvants in cancer vaccines to enhance their efficacy.

Keywords: Adjuvants; Cancer vaccines; Nanotechnology; Rational design; Tumor antigens.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic*
  • Animals
  • Antigens, Neoplasm / immunology
  • Cancer Vaccines* / immunology
  • Cancer Vaccines* / therapeutic use
  • Drug Design
  • Humans
  • Neoplasms / immunology
  • Neoplasms / therapy

Substances

  • Cancer Vaccines
  • Adjuvants, Immunologic
  • Antigens, Neoplasm